Search results
Showing 8056 to 8070 of 8211 results
NICE has today (9 April 2020) published 3 new rapid guidelines on the care of patients with suspected and confirmed COVID-19, and in patients without COVID-19. The guidelines have been designed to maximise the safety of patients whilst enabling services to make the best use of NHS resources.
They cover the management of patients with severe asthma, pneumonia, rheumatological autoimmune, inflammatory and metabolic bone disorders and the management of COVID-19 symptoms in the community.
NICE has today (27 July 2020) published a guideline on the arrangements the NHS should put in place for patients needing elective surgery and other planned treatments and procedures (including diagnostics and imaging) during the COVID-19 pandemic.
NICE has today (29 July 2021) published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations.
Around 1,500 people in England with the rare genetic disorder spinal muscular atrophy are set to benefit from a new treatment after NICE today (19 November 2021) published draft guidance recommending risdiplam (also called Evrysdi and made by Roche) as part of a managed access agreement (MAA).
NICE draft guidance recommends new treatment option for people with early breast cancer
NICE has today (7 May 2020) published draft guidance which recommends trastuzumab emtansine (also called Kadcyla and made by Roche) as an option for some people with HER2-positive early breast cancer.
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis
NICE has today (15 October 2020) issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
NICE draft guidance recommends tucatinib for advanced breast cancer
Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
NICE explores extending its use of data to inform its guidance
Consultation on proposal open until Friday 13 September
NICE extends consultation period for new quality standard on fetal alcohol spectrum disorder
NICE has today (20 August, 2020), released its draft quality standard on fetal alcohol spectrum disorder (FASD) for further public consultation.
Women should be offered the treatment option of their choice, in discussion with their clinician
NICE & SIGN announce latest rapid Covid-19 guideline will address Long Covid
NICE and the Scottish Intercollegiate Guidelines Network (SIGN) have today (5 October 2020) announced they will work with the Royal College of General Practitioners (RCGP) to develop a guideline on persistent effects of Covid-19 (Long Covid) on patients.
Research and knowledge sharing key to collaborative working approach agreed the two agencies
NICE seeks to support new mothers with mental health problems
NICE is calling on general practice staff to assess the mental health of all women who have recently given birth, as fears some may be left unsupported.